Alphamab Oncology

HKEX:9966.HK

3.87 (HKD) • At close November 5, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) HKD.

2023202220212020201920182017
Revenue 218.774166.845146.02104.992-0.7351.223
Cost of Revenue 55.23744.2073.0280000
Gross Profit 163.537122.638142.99304.992-0.7351.223
Gross Profit Ratio 0.7480.7350.9790111
Reseach & Development Expenses 407.524468.238481.361331.241166.65465.60853.221
General & Administrative Expenses 79.33886.77177.25178.208154.29713.3156.631
Selling & Marketing Expenses 0.2250.1690.2990000
SG&A 79.33886.9477.5578.208154.29713.3156.631
Other Expenses -0.0950.4735.360-4.992-27.3720.04
Operating Expenses 469.087468.02570.035480.6315.95996.02365.063
Operating Income -323.325-432.371-415.619-409.449-829.134-131.708-64.818
Operating Income Ratio -1.478-2.591-2.8460-166.093179.195-52.999
Total Other Income Expenses Net 112.732106.6493.202-18.317-3.606-70.925-0.008
Income Before Tax -210.593-325.722-412.417-427.766-832.74-202.633-64.826
Income Before Tax Ratio -0.963-1.952-2.8240-166.815275.691-53.006
Income Tax Expense 124.91140.31428.28403.60616.628-31.765
Net Income -210.593-325.722-412.417-427.766-836.346-149.843-33.061
Net Income Ratio -0.963-1.952-2.8240-167.537203.868-27.033
EPS -0.22-0.35-0.44-0.46-1.56-0.17-0.037
EPS Diluted -0.22-0.35-0.44-0.46-1.56-0.17-0.037
EBITDA -129.296-391.829-387.098-390.469-817.361-125.146-64.304
EBITDA Ratio -0.591-2.348-2.6510-163.734170.267-52.579